03.09.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
03.09.2018 / 12:40
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Hamburg, Germany, 03 September 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)
announced today that its management will be presenting and attending the
following conferences:
Goldman Sachs 8th Annual Biotech Symposium, London, UK
- Date: Friday, 07 September 2018
- Venue: London, UK
- Attendee: Enno Spillner, Chief Financial Officer
J.P. Morgan Cazenove Pan-European Small/Mid Cap Conference, London, UK
- Date: Wednesday, 12 September 2018
- Venue: London, UK
- Attendee: Enno Spillner, Chief Financial Officer
Morgan Stanley 16th Annual Global Healthcare Conference, New York, USA
- Date: Thursday, 13 September, to Friday, 14 September 2018,
Presentation: 14 September 2018, 01.00 pm EDT (06.00 pm BST, 07.00 pm CEST)
- Venue: New York, USA
- Attendee: Dr Werner Lanthaler, Chief Executive Officer
Baader Investment Conference, Munich, Germany
- Date: Monday, 24 September 2018, 02.00 pm CEST (01.00 pm BST, 08.00 am
EDT)
- Venue: Munich, Germany
- Attendee: Enno Spillner, Chief Financial Officer
Berenberg and Goldman Sachs Seventh German Corporate Conference, Munich,
Germany
- Date: Wednesday, 26 September 2018, 02.30 pm CEST (01.30 pm BST, 08.30 am
EDT)
- Venue: Munich, Germany
- Attendee: Dr Werner Lanthaler, Chief Executive Officer
Cantor Global Healthcare Conference 2018, New York, USA
- Date: Monday, 01 October, to Tuesday, 02 October 2018,
Presentation: 02 October 2018, 08.35 am EDT (01.35 pm BST, 02.35 pm CEST)
- Venue: New York, USA
- Attendee: Enno Spillner, Chief Financial Officer
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide and our more than 2,400
employees provide the highest quality stand-alone and integrated drug
discovery and development solutions. We cover all activities from
target-to-clinic to meet the industry's need for innovation and efficiency
in drug discovery and development (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuronal diseases, diabetes and
complications of diabetes, pain and inflammation, oncology, infectious
diseases, respiratory diseases and fibrosis. On this basis, Evotec has built
a broad and deep pipeline of approx. 100 co-owned product opportunities at
clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has
established multiple long-term alliances with partners including, Bayer,
Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi,
Takeda, UCB and others. For additional information please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
03.09.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
720013 03.09.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT